NeilJShahMD

Hematologic Oncology

Physician

Overview of Dr. Shah

Dr. Neil Shah is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Pramukhswami Medical College and has been in practice 7 years. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(256) 693-2804

Education & Training

MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2016 - 2019
Hackensack University Medical Center (Mountainside)Residency, Internal Medicine, 2012 - 2016
Pramukhswami Medical CollegeClass of 2010

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2014 - 2025
NY State Medical License 2019 - 2024
DC State Medical License 2016 - 2020
VA State Medical License 2017 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

7 citations
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
Elisa Baldelli, K. Alex Hodge, Guido Bellezza, Neil J Shah, Guido Gambara
Journal for Immunotherapy of Cancer. 2021-10-01
9 citations
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Kelly N Fitzgerald, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha
European Urology. 2023-03-01
4 citations
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Ritesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, Andrea Knezevic, Samuel Murray
JCO Precision Oncology. 2022-07-01

Lectures

Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, a...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

New Combo Immunotherapy Prolongs Survival in Patients with Advanced Kidney CancerApril 22nd, 2022
Patient Groups Untested in Cancer Immunotherapy Trials Found to Also BenefitMay 30th, 2019